Customer Publication

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer

Authors: Ann-Christin Eder et al.

Journal: Pharmaceuticals (2022)

Institution: German Cancer Research Center

Research Areas: Oncology

Cell Lines: LNCaP, PC-3 (Lymph Node Carcinoma of the Prostate cell line, Caucasian prostate adenocarcinoma)

Summary: This study presents the development and preclinical characterization of a novel class of (prostate-specific membrane antigen) PSMA-targeting hybrid molecules based on the theranostic radiopharmaceutical PSMA-617 for pre- and intraoperative detection of prostate cancer. By analyzing different molecule compositions, the authors addressed the highly challenging introduction of a bulky dye to a low-molecular-weight peptidomimetic and uncovered structure–activity relationships with influence on the internalization profile of the hybrid molecules. With the final lead candidate PSMA-927 featuring properties comparable to those of PSMA-617 in a preclinical proof-of-concept setting, this novel class of PSMA-targeting hybrid molecules warrants subsequent investigations and a potential clinical translation. The new insights uncovered provide a valuable contribution to further advance the field of targeted peptidomimetic hybrid molecule development. HoloMonitor M4 is used for cell proliferation and cell cycle studies.

Keywords: HoloMonitor M4, cell proliferation, cell cycle,psma, hybrid molecules, prostate cancer, guided surgery, theranostics

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2